IDEAYA Biosciences announced that the first patient has been dosed in a Phase I clinical trial of Ide574, its potential first-in-class dual inhibitor targeting Kat6/7.

老虎证券2026/04/06 10:03

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

US Dollar: Resilient as Fed stays hawkish – TD Securities

FXStreet•2026/11/13 09:24

Goldman Sachs: Applied Materials (AMAT.US) Posts Solid Q4 Results, DRAM and Advanced Packaging to Drive Accelerated Growth by 2027

Goldman Sachs maintains its "Buy" rating on Applied Materials but lowers its 12-month target price from $670 to $580.

智通财经•2026/11/13 09:18

Piper Sandler lowers General Mills target price to $35

格隆汇•2026/11/13 08:41

Major Crypto ETFs Bled $1.5 Billion While Wall Street Went Dip Shopping

BeInCrypto•2026/11/13 08:03